BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 35413489)

  • 1. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials.
    Monk BJ; Enomoto T; Kast WM; McCormack M; Tan DSP; Wu X; González-Martín A
    Cancer Treat Rev; 2022 May; 106():102385. PubMed ID: 35413489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
    Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
    Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Top advances of the year: Cervical cancer.
    Podwika SE; Duska LR
    Cancer; 2023 Mar; 129(5):657-663. PubMed ID: 36609769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
    Vergote I; Ray-Coquard I; Lorusso D; Oaknin A; Cibula D; Van Gorp T
    Expert Opin Investig Drugs; 2023 Mar; 32(3):201-211. PubMed ID: 36803278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging immunotherapies for recurrent cervical cancer.
    Liu MC; Tewari KS
    Clin Adv Hematol Oncol; 2022 Feb; 20(2):108-115. PubMed ID: 35120091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin.
    Luu K; Chu A; Chang B
    J Oncol Pharm Pract; 2023 Mar; 29(2):441-449. PubMed ID: 36415085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent or primary metastatic cervical cancer: current and future treatments.
    Gennigens C; Jerusalem G; Lapaille L; De Cuypere M; Streel S; Kridelka F; Ray-Coquard I
    ESMO Open; 2022 Oct; 7(5):100579. PubMed ID: 36108558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
    Eskander RN; Tewari KS
    Clin Ther; 2015 Jan; 37(1):20-38. PubMed ID: 25592089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
    Mutlu L; Tymon-Rosario J; Harold J; Menderes G
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER.
    Jiménez-Lima R; Arango-Bravo E; Galicia-Carmona T; Lino-Silva LS; Trejo-Durán GE; Alvarado-Silva C; Castañeda-Renderos OH; Vanoye-Carlo EG; Torre CF; Dueñas-González A; Cetina-Pérez L
    Rev Invest Clin; 2020; 72(4):231-238. PubMed ID: 33064705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
    Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
    Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
    Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tisotumab vedotin for the treatment of cervical carcinoma.
    Song X; Li R; Wang H; Song P; Guo W; Chen ZS
    Drugs Today (Barc); 2022 May; 58(5):213-222. PubMed ID: 35535813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.
    García E; Ayoub N; Tewari KS
    J Gynecol Oncol; 2024 Jan; 35(1):e30. PubMed ID: 38072400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tisotumab vedotin in recurrent or metastatic cervical cancer.
    Bogani G; Coleman RL; Vergote I; Raspagliesi F; Lorusso D; Monk BJ
    Curr Probl Cancer; 2023 Jun; 47(3):100952. PubMed ID: 36842202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in immunotherapy for cervical cancer.
    Wendel Naumann R; Leath CA
    Curr Opin Oncol; 2020 Sep; 32(5):481-487. PubMed ID: 32740092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
    Kokka F; Bryant A; Brockbank E; Powell M; Oram D
    Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Bladder Cancer.
    Konala VM; Adapa S; Aronow WS
    Am J Ther; 2022 May-Jun 01; 29(3):e334-e337. PubMed ID: 30839322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the state of cervical cancer: updates from prevention to recurrent disease.
    Crafton SM; Venkat PS; Salani R
    Curr Opin Obstet Gynecol; 2024 Feb; 36(1):28-33. PubMed ID: 37873756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential Targeted Therapy for Advanced, Metastatic, and Recurrent Cervical Cancer: A Cost-Effectiveness Analysis of the Patient Journey.
    Richardson MT; Attwood K; Smith G; Liang SY; LaVigne Mager K; Tewari KS; Coleman RL; Kapp DS; Chan JK; Monk BJ
    Cancer Control; 2023; 30():10732748231182795. PubMed ID: 37646470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.